BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosenberg JB, Chen A, De BP, Dyke JP, Ballon DJ, Monette S, Ricart Arbona RJ, Kaminsky SM, Crystal RG, Sondhi D. Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy. Hum Gene Ther 2021;32:563-80. [PMID: 33380277 DOI: 10.1089/hum.2020.269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mashima R, Nakanishi M. Mammalian Sulfatases: Biochemistry, Disease Manifestation, and Therapy. IJMS 2022;23:8153. [DOI: 10.3390/ijms23158153] [Reference Citation Analysis]
2 Rossini L, Durante C, Marzollo A, Biffi A. New Indications for Hematopoietic Stem Cell Gene Therapy in Lysosomal Storage Disorders. Front Oncol 2022;12:885639. [DOI: 10.3389/fonc.2022.885639] [Reference Citation Analysis]
3 Marino M, Holt MG. AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System. Front Neurol 2022;13:870799. [DOI: 10.3389/fneur.2022.870799] [Reference Citation Analysis]
4 Buss N, Lanigan L, Zeller J, Cissell D, Metea M, Adams E, Higgins M, Kim KH, Budzynski E, Yang L, Liu Y, Butt M, Danos O, Fiscella M. Characterization of AAV-mediated dorsal root ganglionopathy. Mol Ther Methods Clin Dev 2022;24:342-54. [PMID: 35229008 DOI: 10.1016/j.omtm.2022.01.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Carvill GL, Matheny T, Hesselberth J, Demarest S. Haploinsufficiency, Dominant Negative, and Gain-of-Function Mechanisms in Epilepsy: Matching Therapeutic Approach to the Pathophysiology. Neurotherapeutics 2021;18:1500-14. [PMID: 34648141 DOI: 10.1007/s13311-021-01137-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Miyake N, Miyake K, Sakai A, Yamamoto M, Suzuki H, Shimada T. Treatment of adult metachromatic leukodystrophy model mice using intrathecal administration of type 9 AAV vector encoding arylsulfatase A. Sci Rep 2021;11:20513. [PMID: 34654893 DOI: 10.1038/s41598-021-99979-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Wang D. Juggling Safety and Efficacy: Finding Ways to Achieve Both. Hum Gene Ther 2021;32:538-9. [PMID: 34143660 DOI: 10.1089/hum.2021.29164.dwa] [Reference Citation Analysis]